Diabetes care最新文献

{"title":"Longitudinal Associations of PFAS Exposure With Insulin Sensitivity and β-Cell Function Among Hispanic Women With a History of Gestational Diabetes Mellitus.","authors":"Ni Kang, Wu Chen, Nosa Osazuwa, Chenyu Qiu, Julianne Cook Botelho, Antonia M Calafat, Dean Jones, Thomas Buchanan, Anny H Xiang, Zhanghua Chen","doi":"10.2337/dc24-2056","DOIUrl":"10.2337/dc24-2056","url":null,"abstract":"<p><strong>Objective: </strong>We investigated associations between per- and polyfluoroalkyl substances (PFAS) and changes in diabetes indicators from pregnancy to 12 years after delivery among women with a history of gestational diabetes mellitus (GDM).</p><p><strong>Research design and methods: </strong>Eighty Hispanic women with GDM history were followed from the third trimester of pregnancy to 12 years after delivery. Oral and intravenous glucose tolerance tests were conducted during follow-up. Plasma PFAS concentrations were measured at the third trimester of pregnancy and first postpartum visit. A linear mixed-effects model was used to analyze associations between PFAS and trajectories of diabetes indicators, adjusted for age, breastfeeding status, daily total calorie intake, and body fat percentage.</p><p><strong>Results: </strong>Increased 2-(N-methyl-perfluorooctane sulfonamido) acetate level was associated with faster increase in concentrations of fasting glucose (P = 0.003). Increased perfluorononanoate (PFNA) and linear perfluorooctanoate (n-PFOA) concentrations were associated with faster increase in fasting insulin concentrations (P = 0.04 for PFNA; P = 0.02 for n-PFOA) and faster decrease in acute insulin response to glucose (P = 0.04 for PFNA; P = 0.02 for n-PFOA).</p><p><strong>Conclusions: </strong>PFAS exposure is associated with glucose intolerance, insulin resistance, and β-cell dysfunction, thus increasing type 2 diabetes risk.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"564-568"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum. 7. Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(Suppl. 1):S146-S166.","authors":"","doi":"10.2337/dc25-er04b","DOIUrl":"10.2337/dc25-er04b","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"666"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","authors":"Kristina M Utzschneider, Mark Tripputi, Nicole M Butera, Andrea Mari, Samuel P Rosin, Mary Ann Banerji, Richard M Bergenstal, Necole Brown, Anders L Carlson, Ralph A DeFronzo, Michaela R Gramzinski, Tasma Harindhanavudhi, Alexandra Kozedub, William I Sivitz, Michael W Steffes, Ashok Balasubramanyam, Neda Rasouli","doi":"10.2337/dc24-2419","DOIUrl":"10.2337/dc24-2419","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate with glycemic deterioration in adults with type 2 diabetes (T2D).</p><p><strong>Research design and methods: </strong>In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), β-cell function parameters derived from mathematical modeling of oral glucose tolerance tests were assessed at baseline (N = 4,712) and 1, 3, and 5 years following randomization to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin. Parameters included insulin secretion rate (ISR), glucose sensitivity (insulin response to glucose), rate sensitivity (early insulin response), and potentiation. Linear mixed-effects models were used to compare changes across treatments. With Cox proportional hazards and Classification And Regression Tree (CART) analyses we evaluated associations between model parameters and glycemic failure (A1C >7.5%; 58.5 mmol/mol).</p><p><strong>Results: </strong>β-Cell function parameters increased variably at year 1 across treatments but subsequently declined for all treatments. Statistically significant changes were noted. Liraglutide led to the greatest increases in ISR, glucose sensitivity and potentiation, remaining above baseline at study end. Sitagliptin improved glucose sensitivity, with modest effects on other parameters. Glimepiride temporarily increased ISR and rate sensitivity but minimally increased glucose sensitivity or potentiation. Rate sensitivity increased most with glargine. Higher β-cell function parameters were protective against glycemic deterioration, but treatment did not alter the relationship between these parameters and glycemic outcomes.</p><p><strong>Conclusions: </strong>Common glucose-lowering medications impact different physiologic components of β-cell function in T2D. Regardless of treatment modality, lower β-cell function associated with early glycemic failure, and β-cell function progressively declined after initial improvement.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"623-631"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Rhee et al. Discrepancy Between Genetically Predicted and Observed BMI Predicts Incident Type 2 Diabetes. Diabetes Care 2024;47:1826-1833.","authors":"Benlin Huang, Kun Zhao","doi":"10.2337/dc24-2242","DOIUrl":"10.2337/dc24-2242","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 3","pages":"e36"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-Glucose Cotransporter 2 Inhibitors and Lower-Extremity Amputation: Is the Guilty Verdict Valid?","authors":"Meng Pan, Til Stürmer","doi":"10.2337/dci24-0101","DOIUrl":"10.2337/dci24-0101","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"338-340"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes.","authors":"Irl B Hirsch, Roy W Beck, Martin C Marak, Yogish Kudva, Halis K Akturk, Anuj Bhargava, Kevin Codorniz, Jamie Diner, Grazia Aleppo, Thomas Blevins, Carol J Levy, Philip Raskin, Kristin Castorino, Anastasios Manessis, David Pickering, Devin W Steenkamp, Ruth S Weinstock, Bruce W Bode, Osama Hamdy, Quang T Nguyen, Mark Kipnes, Katrina J Ruedy, Donna Desjardins, Zehra Haider, Christopher Jacobson, Scott Lee, John B Buse, Klara Rachel Klein, Grenye O'Malley, Mei Mei Church, Adham Mottalib, Jesica D Baran, Corey Kurek, Shafaq Rizvi, Cassandra Donahue, Denisa Tamarez, Astrid Atakov Castillo, Sarah Borgman, Sarah Frey, Peter Calhoun","doi":"10.2337/dc24-1832","DOIUrl":"10.2337/dc24-1832","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring.</p><p><strong>Research design and methods: </strong>At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks.</p><p><strong>Results: </strong>Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI -0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects.</p><p><strong>Conclusions: </strong>In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"353-360"},"PeriodicalIF":16.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Preventive Drug Lists Make High-Deductible Health Plans Safer for People With Diabetes?","authors":"Kaitlynn S Robinson-Ector, Rozalina G McCoy","doi":"10.2337/dci24-0090","DOIUrl":"10.2337/dci24-0090","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 3","pages":"332-334"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comment on Nathan et al. Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial. Diabetes Care 2024;47:2155-2163.","authors":"David M Nathan","doi":"10.2337/dci24-0095","DOIUrl":"10.2337/dci24-0095","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 3","pages":"e34-e35"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There a Place for Inhaled Insulin in the Era of Automated Insulin Delivery?","authors":"Zhengli Bai, Elaine Chow","doi":"10.2337/dci24-0093","DOIUrl":"10.2337/dci24-0093","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 3","pages":"335-337"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comments on Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024;47:1257-1275.","authors":"Guillermo E Umpierrez, Georgia M Davis, Nuha ElSayed, Gian Paolo Fadini, Rodolfo J Galindo, Irl B Hirsch, David C Klonoff, Rozalina G McCoy, Shivani Misra, Robert A Gabbay, Ketan K Dhatariya","doi":"10.2337/dci24-0105","DOIUrl":"10.2337/dci24-0105","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 3","pages":"e42-e43"},"PeriodicalIF":16.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}